Amgen: FDA OKs Tezpire in U.S. for asthsma

 First and Only Biologic to Consistently and Significantly Reduce Exacerbations in a Broad Population of Severe Asthma Patients

Only Biologic for Severe Asthma Approved With no Phenotype or Biomarker Limitations

https://finance.yahoo.com/news/fda-approves-tezspire-tezepelumab-ekko-213000798.html